Literature DB >> 16787919

His-384 allotypic variant of factor H associated with age-related macular degeneration has different heparin binding properties from the non-disease-associated form.

Simon J Clark1, Victoria A Higman, Barbara Mulloy, Stephen J Perkins, Susan M Lea, Robert B Sim, Anthony J Day.   

Abstract

A polymorphism in complement factor H has recently been associated with age-related macular degeneration (AMD), the leading cause of blindness in the elderly. A histidine rather than a tyrosine at residue position 384 in the mature protein increases the risk of AMD. Here, using a recombinant construct, we show that amino acid 384 is adjacent to a heparin-binding site in CCP7 of factor H and demonstrate that the allotypic variants differentially recognize heparin. This functional alteration may affect binding of factor H to polyanionic patterns on host surfaces, potentially influencing complement activation, immune complex clearance, and inflammation in the macula of AMD patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16787919     DOI: 10.1074/jbc.M605083200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  85 in total

1.  Matrix metalloproteinase activity creates pro-angiogenic environment in primary human retinal pigment epithelial cells exposed to complement.

Authors:  Mausumi Bandyopadhyay; Bärbel Rohrer
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-04-18       Impact factor: 4.799

Review 2.  Complement control protein factor H: the good, the bad, and the inadequate.

Authors:  Viviana P Ferreira; Michael K Pangburn; Claudio Cortés
Journal:  Mol Immunol       Date:  2010-08       Impact factor: 4.407

Review 3.  Complement activation, regulation, and molecular basis for complement-related diseases.

Authors:  Goran Bajic; Søren E Degn; Steffen Thiel; Gregers R Andersen
Journal:  EMBO J       Date:  2015-10-21       Impact factor: 11.598

Review 4.  Complement pathway biomarkers and age-related macular degeneration.

Authors:  M Gemenetzi; A J Lotery
Journal:  Eye (Lond)       Date:  2015-10-23       Impact factor: 3.775

5.  Heparan sulfate, including that in Bruch's membrane, inhibits the complement alternative pathway: implications for age-related macular degeneration.

Authors:  Una Kelly; Ling Yu; Pallavi Kumar; Jin-Dong Ding; Haixiang Jiang; Gregory S Hageman; Vadim Y Arshavsky; Michael M Frank; Michael A Hauser; Catherine Bowes Rickman
Journal:  J Immunol       Date:  2010-09-27       Impact factor: 5.422

Review 6.  Progress in defining the molecular biology of age related macular degeneration.

Authors:  Andrew Lotery; Dorothy Trump
Journal:  Hum Genet       Date:  2007-07-21       Impact factor: 4.132

7.  Activation of Rap1 inhibits NADPH oxidase-dependent ROS generation in retinal pigment epithelium and reduces choroidal neovascularization.

Authors:  Haibo Wang; Yanchao Jiang; Dallas Shi; Lawrence A Quilliam; Magdalena Chrzanowska-Wodnicka; Erika S Wittchen; Dean Y Li; M Elizabeth Hartnett
Journal:  FASEB J       Date:  2013-09-16       Impact factor: 5.191

8.  Individuals homozygous for the age-related macular degeneration risk-conferring variant of complement factor H have elevated levels of CRP in the choroid.

Authors:  P T Johnson; K E Betts; M J Radeke; G S Hageman; D H Anderson; L V Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-01       Impact factor: 11.205

Review 9.  The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited.

Authors:  Don H Anderson; Monte J Radeke; Natasha B Gallo; Ethan A Chapin; Patrick T Johnson; Christy R Curletti; Lisa S Hancox; Jane Hu; Jessica N Ebright; Goldis Malek; Michael A Hauser; Catherine Bowes Rickman; Dean Bok; Gregory S Hageman; Lincoln V Johnson
Journal:  Prog Retin Eye Res       Date:  2009-12-02       Impact factor: 21.198

10.  Anticomplement therapy.

Authors:  Prathit A Kulkarni; Vahid Afshar-Kharghan
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.